Jan A Burger

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia
    Jan A Burger
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Curr Hematol Malig Rep 7:26-33. 2012
  2. pmc Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, U S A
    Oncotarget 2:737-8. 2011
  3. doi request reprint Bruton's tyrosine kinase (BTK) inhibitors in clinical trials
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, PO Box 301402, Houston, TX, 77230 1402, USA
    Curr Hematol Malig Rep 9:44-9. 2014
  4. ncbi request reprint The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Semin Cancer Biol 24:71-81. 2014
  5. ncbi request reprint B cell receptor signaling in chronic lymphocytic leukemia
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Electronic address
    Trends Immunol 34:592-601. 2013
  6. doi request reprint The CLL cell microenvironment
    Jan A Burger
    Unit 428, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 301402, Houston, TX, 77230 1402, USA
    Adv Exp Med Biol 792:25-45. 2013
  7. doi request reprint Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Blood 121:1501-9. 2013
  8. doi request reprint Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Curr Opin Oncol 24:643-9. 2012
  9. doi request reprint The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL
    Jan A Burger
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, PO Box 301402, Houston, TX 77230 1402, USA 1 713 563 1487 or 1 713 792 1865 1 713 794 4297
    Expert Opin Med Diagn 6:49-57. 2012
  10. doi request reprint The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Semin Cancer Biol 21:308-12. 2011

Detail Information

Publications55

  1. doi request reprint Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia
    Jan A Burger
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Curr Hematol Malig Rep 7:26-33. 2012
    ..This article reviews key biologic aspects of BCR-associated kinases in CLL and other B cell neoplasias, and develops perspectives for future development of this exciting new class of kinase inhibitors...
  2. pmc Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, U S A
    Oncotarget 2:737-8. 2011
    ..PI3K signaling is now targeted in first clinical trials in patients with B cell malignancies, including Chronic Lymphocytic Leukemia (CLL), which represent one of the first molecularly targeted therapies for B cell malignancies...
  3. doi request reprint Bruton's tyrosine kinase (BTK) inhibitors in clinical trials
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, PO Box 301402, Houston, TX, 77230 1402, USA
    Curr Hematol Malig Rep 9:44-9. 2014
    ..This review discusses the clinical advances with BTK inhibitor therapy, as well as its pathophysiological basis, and outlines perspectives for future use of BTK inhibitors. ..
  4. ncbi request reprint The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Semin Cancer Biol 24:71-81. 2014
    ..Clinically relevant aspects of new targeted therapeutics will be discussed, along with an outlook into future therapeutic strategies. ..
  5. ncbi request reprint B cell receptor signaling in chronic lymphocytic leukemia
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Electronic address
    Trends Immunol 34:592-601. 2013
    ..Here, we discuss the evolution of this field, from BCR-related prognostic markers, to mechanisms of BCR activation, and targeting of BCR-associated kinases, the emerging Achilles' heel in CLL pathogenesis. ..
  6. doi request reprint The CLL cell microenvironment
    Jan A Burger
    Unit 428, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 301402, Houston, TX, 77230 1402, USA
    Adv Exp Med Biol 792:25-45. 2013
    ..The rapid progress in dissecting the CLL microenvironment and the promising early results of these new targeted treatments in CLL indicate that CLL has become a role model for microenvironment-dependent cancers. ..
  7. doi request reprint Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Blood 121:1501-9. 2013
    ..In addition, we outline how these discoveries are changing our understanding of CLL biology and therapy...
  8. doi request reprint Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Curr Opin Oncol 24:643-9. 2012
    ..Consequently, there is growing interest in targeting the tumor-microenvironment cross-talk. This review highlights recent therapeutic advances in targeting the microenvironment in chronic lymphocytic leukemia (CLL)...
  9. doi request reprint The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL
    Jan A Burger
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, PO Box 301402, Houston, TX 77230 1402, USA 1 713 563 1487 or 1 713 792 1865 1 713 794 4297
    Expert Opin Med Diagn 6:49-57. 2012
    ..e., CCL3 plasma levels). The negative prognostic impact of BCR-related risk factors may improve with the use of these new, targeted agents...
  10. doi request reprint The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Semin Cancer Biol 21:308-12. 2011
    ..In this review, we summarize key cellular and molecular interactions between MCL cells and their microenvironment, and update new clinical developments in this area...
  11. doi request reprint Nurture versus nature: the microenvironment in chronic lymphocytic leukemia
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Hematology Am Soc Hematol Educ Program 2011:96-103. 2011
    ..These findings indicate that interplay between leukemia-inherent and environmental factors, nature and nurture determines disease progression in CLL...
  12. ncbi request reprint The microenvironment in mature B-cell malignancies: a target for new treatment strategies
    Jan A Burger
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 114:3367-75. 2009
    ..Such approaches hopefully will help eliminating residual disease, thereby improving our current therapeutic efforts...
  13. ncbi request reprint The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets
    Jan A Burger
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leuk Lymphoma 52:94-8. 2011
    ..Also, we outline future prospects for therapeutic targeting of the microenvironment in HCL, focusing on CXCR4 and kinase inhibitors (Syk, Btk, phosphatidylinositol 3-kinase [PI3K]) that target B cell receptor signaling...
  14. doi request reprint The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
    Julia Hoellenriegel
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:3603-12. 2011
    ..These data provide an explanation for the clinical activity of CAL-101, and a roadmap for future therapeutic development...
  15. ncbi request reprint CXCR4 chemokine receptor antagonists: perspectives in SCLC
    Jan A Burger
    University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX 77230 1402, USA
    Expert Opin Investig Drugs 18:481-90. 2009
    ..Here, we summarize preclinical data about CXCR4 in SCLC, and the current status of the preclinical and clinical development of CXCR4 antagonists...
  16. doi request reprint Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting
    Jan A Burger
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Semin Cancer Biol 20:424-30. 2010
    ..CXCR4, the most prominent chemokine receptor in CLL, is now targeted in a first clinical trial, emphasizing that chemokines and their receptors have become a highly dynamic translational research field...
  17. doi request reprint Potential of CXCR4 antagonists for the treatment of metastatic lung cancer
    Jan A Burger
    Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Expert Rev Anticancer Ther 11:621-30. 2011
    ..In addition, we review the current status of the preclinical and clinical development of CXCR4 antagonists...
  18. ncbi request reprint CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
    Jan A Burger
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Blood 107:1761-7. 2006
    ..As such, CXCR4 antagonists, although initially developed for treatment of AIDS, actually may become effective agents for the treatment of neoplastic disease...
  19. ncbi request reprint The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target
    Jan A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Br J Haematol 137:288-96. 2007
    ....
  20. doi request reprint High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
    Jan A Burger
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 113:3050-8. 2009
    ..Through these chemokines, CLL cells can recruit accessory cells and thereby actively create a supportive microenvironment...
  21. ncbi request reprint Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 122:1214-21. 2013
    ..2). At 3 and 12 months, negative MRD by MFC was associated with improved survival (P = .04 and .001). MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR...
  22. ncbi request reprint B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
    Maite P Quiroga
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 114:1029-37. 2009
    ..R406 effectively blocks these BCR-dependent responses in CLL cells, providing an explanation for the activity of R406 in patients with CLL...
  23. doi request reprint Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
    Antonina V Kurtova
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 114:4441-50. 2009
    ..They also provide a reliable, validated tool for future investigations into the mechanism of MSC-CLL cross talk and for drug testing in a more relevant fashion than the commonly used suspension cultures...
  24. doi request reprint Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
    Antonina V Kurtova
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 113:4604-13. 2009
    ..Both agents blocked functional responses to the respective ligands and inhibited adhesive interactions between MCL cells and MSCs. These findings provide a rationale to further investigate the therapeutic potential of these drugs in MCL...
  25. pmc Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
    Lorenzo Falchi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Am J Hematol 88:1024-9. 2013
    ..Deeper MR at 18 or 24 months are not associated with a benefit in TFS or OS. Furthermore, achieving susMR4·5 does not appear to further reduce the risk of transformation or death...
  26. doi request reprint The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
    Sabine Ponader
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Blood 119:1182-9. 2012
    ..Our data demonstrate that PCI-32765 effectively inhibits CLL cell migration and survival, possibly explaining some of the characteristic clinical activity of this new targeted agent...
  27. ncbi request reprint Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia
    Xavier C Badoux
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 31:584-91. 2013
    ..Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL...
  28. doi request reprint Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
    Matthias Niedermeier
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 113:5549-57. 2009
    ....
  29. pmc AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
    Kumudha Balakrishnan
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:149-53. 2009
    ..Collectively, these data demonstrate that AT-101 induces apoptosis in CLL B cells and overcomes microenvironment-mediated resistance while sparing normal stromal cells...
  30. pmc Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells
    Kumudha Balakrishnan
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:1083-91. 2010
    ....
  31. pmc Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
    Wan Zhang
    Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Cell Biol 14:276-86. 2012
    ..This stromal-leukaemia interaction is critical for CLL cell survival and represents a key biochemical pathway for effectively targeting leukaemia cells to overcome drug resistance in vivo...
  32. ncbi request reprint Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
    Blood 123:3797-802. 2014
    ..Whether ruxolitinib treatment would benefit patients with CLL remains to be determined. ..
  33. ncbi request reprint The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
    Julia Hoellenriegel
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX and
    Blood 123:1032-9. 2014
    ..These data demonstrate that NOX-A12 effectively interferes with CLL cell migration and BMSC-mediated drug resistance, and establishes a rationale for clinical development of NOX-A12 in combination with conventional agents in CLL. ..
  34. ncbi request reprint CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia
    Pietro Bulian
    Pietro Bulian, Antonella Zucchetto, and Valter Gattei, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Centro di Riferimento Oncologico, Aviano Lilla Cro and Luca Baldini, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico and Università degli Studi, Milan Gianluca Gaidano and Davide Rossi, Amedeo Avogadro University of Eastern Piedmont, Novara Giovanni Del Poeta, Tor Vergata University, S Eugenio Hospital, Rome, Italy Tait D Shanafelt, Mayo Research Center, Rochester, NY Chris Fegan and Chris Pepper, Institute of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom Holger Nückel, University of Duisburg Essen, Essen, Germany and Antonina V Kurtova, Alessandra Ferrajoli, and Jan A Burger, University of Texas MD Anderson Cancer Center, Houston, TX
    J Clin Oncol 32:897-904. 2014
    ..A worldwide multicenter analysis was performed using published and unpublished CLL series to evaluate the impact of CD49d as an overall (OS) and treatment-free survival (TFS) predictor...
  35. pmc The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells
    Stefania Fiorcari
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America Hematology Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    PLoS ONE 8:e83830. 2013
    ..These findings demonstrate that idelalisib interferes with integrin-mediated CLL cell adhesion to EC and BMSC, providing a novel mechanism to explain idelalisib-induced redistribution of CLL cells from tissues into the blood. ..
  36. ncbi request reprint Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
    Susan O'Brien
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 15:48-58. 2014
    ..We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia...
  37. pmc CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
    Mariela Sivina
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Blood 117:1662-9. 2011
    ..Collectively, CCL3 is a novel, robust, and independent prognostic marker in CLL that can easily and reliably be measured by ELISA. CCL3 therefore should become useful for risk assessment in patients with CLL...
  38. ncbi request reprint Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
    Jan A Burger
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 54:2385-91. 2013
    ..This review discusses the discovery, preclinical and clinical development of ibrutinib, its pathophysiological basis, and outlines perspectives for future use of ibrutinib...
  39. doi request reprint Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 114:2037-43. 2009
    ..Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease...
  40. ncbi request reprint Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
    William G Wierda
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 29:4088-95. 2011
    ..We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL...
  41. ncbi request reprint Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
    Xavier C Badoux
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:3489-98. 2011
    ..Lenalidomide therapy was well tolerated and induced durable remissions in this population of elderly, symptomatic patients with CLL. This study was registered at www.clinicaltrials.gov as #NCT00535873...
  42. ncbi request reprint The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach
    Mariela Sivina
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston, TX, USA
    Br J Haematol 166:177-88. 2014
    ..Interestingly, ibrutinib inhibited also CXCL12-induced signalling, a key pathway for bone marrow homing. Collectively, our data support the clinical development of ibrutinib in patients with HCL. ..
  43. ncbi request reprint Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
    Marina Y Konopleva
    Authors Affiliations Department of Leukemia Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Division of Hematology Department of Medicine Department of Epidemiology, University of Washington, Seattle, Washington and National Cancer Institute, Rockville, Maryland
    Clin Cancer Res 20:2226-35. 2014
    ..Subsequently, we conducted a phase II trial of MK-2206 (200 mg weekly) in adults requiring second salvage therapy for relapsed/refractory AML, and assessed target inhibition via reverse phase protein array (RPPA)...
  44. ncbi request reprint Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies
    Sabine Ponader
    All authors The University of Texas MD Anderson Cancer Center, Houston, TX
    J Clin Oncol 32:1830-9. 2014
    ..In this article, we discuss key discoveries related to BTK and clinically relevant aspects of BTK inhibitors, and we provide an outlook into clinical development and open questions regarding BTK inhibitor therapy. ..
  45. pmc Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer 12:50. 2013
    ....
  46. ncbi request reprint CXCR4 is a prognostic marker in acute myelogenous leukemia
    Anke C Spoo
    Department of Medicine, Freiburg University Hospital, Germany
    Blood 109:786-91. 2007
    ..These findings warrant further investigation into the role of CXCR4 in AML and suggest that CXCR4 should be incorporated into the risk assessment of AML patients...
  47. ncbi request reprint CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis)
    Jan A Burger
    Division of Haematology Oncology, Department of Medicine, Freiburg University Hospital, Hugstetterstrasse 55, D 79106 Freiburg, Germany
    Br J Haematol 122:579-89. 2003
    ..These observations suggest a central role of marrow stromal cells for HSC trafficking and homing within the marrow microenvironment...
  48. ncbi request reprint Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
    Meike Burger
    Department of Medicine, Division of Hematology Oncology, Freiburg University Hospital, Hugstetterstr 55, D 79106 Freiburg, Germany
    Blood 106:1824-30. 2005
    ..As such, small molecular CXCR4 antagonists may have activity in the treatment of patients with this disease...
  49. ncbi request reprint Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells
    Meike Burger
    Department of Internal Medicine, Freiburg University Hospital, Freiburg, Germany
    Oncogene 22:8093-101. 2003
    ....
  50. ncbi request reprint Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells
    Jan A Burger
    Department of Medicine, Freiburg University Hospital, Germany
    Leuk Lymphoma 43:461-6. 2002
    ..Conceivably, CXCR4, and possibly other chemokine receptors, may represent a novel target for the development of effective treatment of this disease...
  51. ncbi request reprint KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway
    Meike Burger
    Department of Internal Medicine, Freiburg University Hospital, Freiburg, Germany
    Oncogene 24:2067-75. 2005
    ....
  52. ncbi request reprint No cell is an island unto itself: the stromal microenvironment in chronic lymphocytic leukemia
    Jan A Burger
    Leuk Res 31:887-8. 2007
  53. ncbi request reprint Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia
    Andrea Bürkle
    Department of Medicine, Division of Hematology Oncology, Freiburg University Hospital, Freiburg, Germany
    Blood 110:3316-25. 2007
    ..These data suggest that CXCR5 plays a role in CLL cell positioning and cognate interactions between CLL and CXCL13-secreting CD68+ accessory cells in lymphoid tissues...
  54. ncbi request reprint Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia
    Nobuhiro Tsukada
    Department of Medicine, Division of Hematology Oncology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0663, USA
    Blood 99:1030-7. 2002
    ..The interaction between CLL cells and NLCs may represent a novel target for therapy of patients with this disease...
  55. ncbi request reprint CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells
    Tanja N Hartmann
    Department of Medicine, Division of Hematology Oncology, Freiburg University Hospital, Hugstetterstr 55, D 79106 Freiburg, Germany
    Oncogene 24:4462-71. 2005
    ..Therefore, CXCR4 antagonists in combination with cytotoxic drugs should be explored in SCLC to overcome CXCL12-mediated adhesion and survival signals in the tumor microenvironment...